COMPOSITIONS AND METHODS FOR NEOADJUVANT TREATMENT IN CANCER COMPRISING ANTI-CD39 ANTIBODIES

COMPOSITIONS AND METHODS FOR NEOADJUVANT TREATMENT IN CANCER COMPRISING ANTI-CD39 ANTIBODIES

The present invention relates to antibodies that inhibit the enzymatic activity of human CD39 and methods of using the compounds to treat cancer, including in combination with an anti-PD(L)1 antibody. The anti-CD39 antibody and the anti-PD(L)1 antibody can be administered as neoadjuvant therapy to t...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: COOPER, Zachary, FAN, Chunling, ANCERIZ, Nadia, EYLES, James, FRAENKEL, Paula, TU, Eric, PATUREL, Carine, DENIS, Caroline
Format: Patent
Sprache:eng ; fre
Schlagworte:
CHEMISTRY
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The present invention relates to antibodies that inhibit the enzymatic activity of human CD39 and methods of using the compounds to treat cancer, including in combination with an anti-PD(L)1 antibody. The anti-CD39 antibody and the anti-PD(L)1 antibody can be administered as neoadjuvant therapy to treat lung cancer. The invention also relates to dosing regimens for combination treatment with anti-CD39 antibody and an anti-PD(L)1 antibody. La présente invention concerne des anticorps qui inhibent l'activité enzymatique de CD39 humain et des méthodes d'utilisation des composés pour traiter le cancer, y compris en combinaison avec un anticorps anti-PD(L)1. L'anticorps anti-CD39 et l'anticorps anti-PD(L)1 peuvent être administrés en tant que thérapie néoadjuvante pour traiter le cancer du poumon. L'invention concerne également des schémas posologiques pour un traitement combiné avec un anticorps anti-CD39 et un anticorps anti-PD(L)1.